Research shows that people with fatty liver disease (MASLD) have lower levels of hydrogen sulfide, a gas-based signal molecule, in their liver. A 2026 study covered in Gram Research analysis found that sleeve gastrectomy, a weight-loss surgery, moved these levels closer to normal in obese rats. The work is early and small, so cause is not proven.
Fatty liver disease, now called MASLD, is closely tied to obesity and blood sugar problems. A new study looked at a natural gas-based signal in the liver called hydrogen sulfide, which helps control how the body handles sugar, fat, and cell stress. Researchers compared liver tissue from five people with fatty liver disease to five people without it. They then studied obese rats that received sleeve gastrectomy, a type of weight-loss surgery that makes the stomach smaller. People with fatty liver disease had less hydrogen sulfide and lower levels of one of the enzymes that makes it. In the rats, surgery reduced body weight, improved blood sugar and fat levels, and reduced liver fat. It also moved hydrogen sulfide levels closer to the pattern seen in healthy animals. According to Gram Research analysis, this is an early finding from a very small study. It does not yet show that these gas changes cause the benefits of surgery.
Key Statistics
A 2026 study of five people with fatty liver disease and five people without it found that the fatty liver group had a reduced hydrogen sulfide pool and lower levels of the CSE enzyme in liver tissue.
In a 2026 rat study, sleeve gastrectomy reduced body weight and food intake compared with sham surgery while increasing the hydrogen sulfide pool and CSE enzyme levels in the liver.
The Quick Take
- What they studied: The researchers wanted to know whether the liver’s supply of hydrogen sulfide, a gas-based signal that helps manage sugar and fat, is different in people with fatty liver disease. They also asked whether weight-loss surgery changes these levels in obese animals.
- Who participated: The human part included five adults with fatty liver disease (MASLD) and five people without it, studied through liver tissue samples. The animal part used obese rats fed a high-fat diet, with some receiving sleeve gastrectomy surgery and others receiving a sham operation. The exact number of rats was not specified in the summary.
- Key finding: People with fatty liver disease had a smaller hydrogen sulfide supply and less of one enzyme that makes it in their liver tissue. In obese rats, sleeve gastrectomy reduced body weight and liver fat, and it moved these gas levels closer to the healthy pattern. Because only five people per group were studied, these results are preliminary.
- What it means for you: This research is not yet a basis for changing your diet or treatment. It does suggest that hydrogen sulfide may be one of several biological pathways involved in fatty liver disease. If you have fatty liver disease, talk with your doctor about proven steps such as weight loss, healthy eating, and regular activity.
The Research Details
The study had two parts. In the first part, researchers examined liver tissue from five people with fatty liver disease and five people without it. They looked at the tissue under a microscope to check for fat buildup, measured the amount of hydrogen sulfide and related compounds, and checked how much of three key enzymes were being produced. These enzymes are CBS, CSE, and MPST, and each helps make or process hydrogen sulfide.
In the second part, researchers used obese rats fed a high-fat diet to copy the human condition in a controlled setting. Some rats received sleeve gastrectomy, a surgery that removes part of the stomach, while others received a sham operation that did not change the stomach. The team then tracked body weight, food intake, blood sugar and fat levels, liver function, and liver tissue changes.
Using both human tissue and animal experiments allowed the researchers to look for matching patterns across two different settings. This approach is useful for early investigation because it can reveal biological clues that are then tested in larger studies.
Combining human tissue samples with an animal model helps researchers check whether a pattern seen in people also appears in a living system where they can control diet, surgery, and timing. If the same changes show up in both, that is a clue worth following. However, the human sample is very small, so the study can only point toward possible links rather than prove them.
The study used several standard lab methods, including microscope review of tissue, chemical measurement, and tests that measure how much of each enzyme is being made. Comparing surgery and sham groups in rats is a sound design for isolating the effect of the operation. The main weaknesses are the very small human group, the unspecified number of rats, and the fact that the paper was published in a journal that is not widely known for top-tier clinical evidence. Readers should treat the results as early and exploratory.
What the Results Show
The first main finding is that people with fatty liver disease had clear fat buildup in their liver tissue. Their livers also had a smaller pool of hydrogen sulfide and related compounds. One enzyme that makes hydrogen sulfide, called CSE, was produced at lower levels, while another enzyme, MPST, was produced at higher levels. A third enzyme, CBS, did not change. In simple terms, the liver seemed to be producing and handling this gas signal differently in fatty liver disease.
The obese rats showed a similar pattern. Their livers had changes in hydrogen sulfide-related chemistry that resembled the changes seen in the people with fatty liver disease. This matching pattern is what makes the animal experiment useful, since it suggests the biology may be comparable across the two settings.
The second main finding comes from the surgery experiment. Rats that received sleeve gastrectomy weighed less and ate less food than sham rats. Their blood sugar and fat levels improved, their liver function looked better, and the fat in their livers decreased. These effects were the expected benefits of weight-loss surgery.
The third main finding is that the surgery was linked with a bigger hydrogen sulfide pool in the liver, higher CSE enzyme levels, and lower MPST enzyme levels. CBS stayed about the same. These shifts moved the rats’ liver chemistry toward the pattern seen in healthy controls. The authors describe this as a parallel change, not proof that the gas signal causes the improvement.
The study also reported that the liver changes followed the same general direction as the metabolic improvements. Less liver fat, better blood sugar control, and improved liver function all appeared alongside the shifts in hydrogen sulfide-related chemistry. This consistency makes the idea worth testing further, even though it does not establish a cause.
Another useful point is that CBS levels did not change in either the human or animal results. This may suggest that the differences are tied more closely to CSE and MPST, but this would need to be confirmed in larger studies. For readers, the main takeaway is that the study looked at several parts of one biological system rather than a single marker.
Hydrogen sulfide has been studied for its role in regulating blood vessels, inflammation, and metabolism. Earlier research has connected it with liver fat handling and insulin response, so the finding that it changes in fatty liver disease fits with the broader picture. Sleeve gastrectomy is already known to improve fatty liver and blood sugar in many patients, and this study adds a possible biological explanation. Still, the specific link between this gas pathway and surgical benefit is newer and less established than the surgery’s known effects.
The most important limitation is the small size of the human group, which included only five people with fatty liver disease and five without it. Small groups can produce results that do not hold up in larger populations. The rat experiment also did not report the exact number of animals, which makes it harder to judge how reliable the comparisons are.
The study measured these gas-related changes at one point in time in the liver, so it cannot show how they develop over months or years. It also cannot prove that hydrogen sulfide causes the metabolic improvements after surgery. The authors themselves note that whether these changes contribute to the benefits remains to be determined.
Finally, rats are not people. Diet, body size, and liver biology differ across species, so results in animals may not translate directly to humans. Larger human studies that track hydrogen sulfide levels before and after surgery would be needed to test whether these changes matter for patients.
The Bottom Line
Based on this study alone, there is low confidence in any specific hydrogen sulfide-based treatment or supplement for fatty liver disease. The findings are best viewed as a promising research lead. Established steps with stronger evidence, such as losing weight, eating a balanced diet, staying physically active, and reducing alcohol, remain the most reliable approaches. Decisions about weight-loss surgery should be made with a medical team based on proven benefits and risks.
People with fatty liver disease, obesity, or type 2 diabetes may find this research interesting, especially if they are considering weight-loss surgery. Researchers studying liver disease and metabolism should also pay attention. Readers looking for a ready-to-use treatment or supplement should not apply these findings yet, because the study does not test any product or therapy in people.
Lab-based discoveries like this usually take years to move into clinical testing. Human trials would need to confirm the pattern, test whether changing hydrogen sulfide levels affects outcomes, and check safety. For people who choose weight-loss surgery or lifestyle changes, the well-established liver and blood sugar benefits often appear over months, but any link to this specific gas pathway is not yet proven.
Frequently Asked Questions
Does fatty liver disease affect hydrogen sulfide levels in the body?
A 2026 study found that people with fatty liver disease, now called MASLD, had a smaller hydrogen sulfide pool and lower CSE enzyme levels in liver tissue. The study included only five people with the condition and five without, so the finding is preliminary and needs larger confirmation.
Can weight-loss surgery change liver chemistry linked to fatty liver disease?
In obese rats, sleeve gastrectomy increased the liver’s hydrogen sulfide pool and CSE enzyme levels while reducing MPST enzyme levels. These shifts moved liver chemistry toward healthy patterns, but the study did not prove these changes cause the surgery’s benefits.
What is hydrogen sulfide and why does it matter for the liver?
Hydrogen sulfide is a gas-based signal molecule the body produces in small amounts. It helps regulate how the liver handles sugar, fat, and cell stress. Researchers are studying it as one possible factor in fatty liver disease, but its exact role is still being worked out.
Is there a supplement that raises hydrogen sulfide to treat fatty liver disease?
No supplement has been proven to treat fatty liver disease through hydrogen sulfide. This study only measured levels in tissue and rats. Proven steps include weight loss, balanced eating, regular physical activity, and limiting alcohol, which are best discussed with a doctor.
Want to Apply This Research?
- Track weekly body weight, waist measurement, and a simple liver-health check if your doctor recommends one, such as periodic liver enzyme tests. Record these alongside daily meal logs and servings of vegetables, protein, and whole grains. These measurements are practical, widely available, and directly relevant to fatty liver disease.
- Use the app to set one realistic habit each week, such as walking 20 to 30 minutes after dinner, swapping sugary drinks for water, or adding one vegetable to each meal. Small, consistent changes support weight loss and liver fat reduction, which are the proven steps linked with improvement in fatty liver disease.
- Review your trends monthly rather than daily, focusing on weight, waist size, and how often you meet your nutrition and activity goals. Share these summaries with your healthcare provider at regular checkups. If you have had weight-loss surgery, track symptoms, nutrient intake, and any changes in energy, and report concerns promptly to your medical team.
This article summarizes an early research study involving five people and an animal experiment. It is for general information only and is not medical advice. Findings about hydrogen sulfide and fatty liver disease are preliminary and have not been proven to guide treatment. Anyone with fatty liver disease or considering weight-loss surgery should consult a qualified healthcare professional before making changes to diet, medication, or treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.